Gene: CXorf40A

91966
CXorf40|EOLA1
chromosome X open reading frame 40A
protein-coding
Xq28
Ensembl:ENSG00000197620 MIM:300954 Vega:OTTHUMG00000022622 UniprotKB:Q8TE69
NC_000023.11
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
NA (AD)  NA (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs3747443chrX:149541185 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
EBNA1BP20.911
MAD2L1BP0.911
EID20.907
C1orf2160.906
SMYD30.905
DCTPP10.904
GABARAPL10.904
PCMT10.9
TIMM17A0.898
CIAPIN10.898

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MTRNR2L6-0.461
OR4F5-0.459
REST-0.45
CSAG1-0.449
HEY2-0.448
MTRNR2L10-0.445
P2RY14-0.439
CDC14A-0.437
MTRNR2L9-0.434
S100A12-0.433

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXORF40A mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXORF40A mRNA"27188386
D001554BenzeneBenzene results in increased expression of CXORF40A mRNA15929907
D003976DiazinonDiazinon results in increased methylation of CXORF40A gene22964155
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of CXORF40A mRNA23649840
D010936Plant ExtractsPlant Extracts results in increased expression of CXORF40A mRNA23557933
D012643SeleniumSelenium results in decreased expression of CXORF40A mRNA19244175
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXORF40A mRNA"27188386
D014635Valproic AcidValproic Acid results in increased expression of CXORF40A mRNA24935251|2627250

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI15541360  
GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal